PHILADELPHIA, PA -- (Marketwired) -- 05/10/17 --
Aevi Genomic Medicine, Inc. (NASDAQ: GNMX)
Company to initiate a Phase 2 clinical trial in 2H 2017, targeting a specific genetic subset of patients identified by a responder analysis of the SAGA trial
Responder subset is approximately 10% of the US pediatric ADHD population and a total addressable market of $2 to $3 billion
Genetic subset had a 90% response rate and stimulant-like effect in the SAGA t...
PHILADELPHIA, PA -- (Marketwired) -- 05/03/17 --
Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today it will host a conference call and live audio webcast on Wednesday, May 10, 2017 at 8:30 a.m. EDT to report financial results for the first quarter and discuss recent business updates.
In order to participate in the conference call, please dial (888) 481-2845 (domestic) or (719) 325-2327 (international). The conference passcode is 9118660.
The live webcast can be accessed...
PHILADELPHIA, PA -- (Marketwired) -- 04/27/17 --
Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference on Thursday, May 4, 2017 at 1:10 p.m. EDT at the InterContinental Boston Hotel in Boston, MA.
A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at www.aevigenomics.com or y...